Ocular Therapeutix (OCUL) Misses Q2 EPS by 8c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.64), $0.08 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $438 thousand versus the consensus estimate of $490 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• General Mills beats estimates as cost savings offset volumes
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print